Search
Site Logo

Radioligand Therapy & Theranostics Services

Radiopharmaceutical therapies represent an effective way to treat solid cancers by using tumor targeting small molecules, peptides or biologics to deliver a cytotoxic payload that induces DNA damage in tumor cells, while limiting damage to normal and healthy tissue.

divider

Overview

Streamlined development, evaluation and clinical translation of radiopharmaceuticals requires a partner that has extensive scientific, regulatory and operational expertise. Working with a CRO that provides a complete solution ensures data is delivered in a timely manner to make a go/no-go decision on your imaging or therapeutic candidates.

Services Include:

  • Single-site, first-in-human through multi-site, late phase clinical study support
  • Investigational New Drug (IND)/Clinical Trial Application (CTA) submission support with clinical protocol development
  • Preclinical and clinical dosimetry and advanced quantitative image analysis
  • Radiochemistry development – conjugation, radiolabeling, stability and immunoreactivity
  • Preclinical proof-of-concept studies – biodistribution, efficacy, toxicology
  • Good manufacturing practice (GMP) radiochemistry development and production support for imaging agents

Clinical Radiopharmaceutical Therapy Solutions

Seamless transition of your radiopharmaceutical into the clinic requires an imaging partner with experience supporting first-in-human, single-site and late phase, multi-site global clinical studies. Perceptive has the unique blend of scientific expertise and operational experience to deliver on studies from Phase 0-III.

Clinical radiopharmaceutical therapeutic development services include:

  • First-in-human, single-site clinical trial support
  • Study design and consultation
  • Criteria-based centralized independent reviews and internal analysis
  • Late stage, global multi-center clinical trial support with response criteria reads
  • Advanced image analytics including dosimetry
  • Safety profile and therapeutic efficacy studies

Radiochemistry - Radioisotopes for Targeted Radiotherapy

Our team has experience with novel and commercially available radioisotopes used for targeted radiotherapy. Our capabilities for novel radiotracers span preclinical to first-in-human clinical studies and GMP production with Perceptive’s CMO partners.

Perceptive has experience with many isotopes including:

  • 225Ac
  • 177Lu
  • 131I
  • 111ln
  • 68Ga/177Lu
  • 111In/225Ac
  • 203Pb/212Pb
  • 67Cu/64Cu

Dosimetry and Advanced Image Analytics

Our in-house image analytics team has experience supporting preclinical and clinical radiopharmaceutical therapy studies, spanning from customized and automated image processing techniques using deep learning to dosimetry analysis for safety profile analysis
Expand

Dosimetry and Advanced Image Analytics

Our in-house image analytics team has experience supporting preclinical and clinical radiopharmaceutical therapy studies, spanning from customized and automated image processing techniques using deep learning to dosimetry analysis for safety profile analysis. Some advanced image analytic techniques include:
  • Algorithms for automated and semi automated lesion identification
  • Image quality control and co-registration
  • Preclinical dosimetry safety studies and validated clinical workflows
  • Extrapolating dosimetry of therapeutics from imaging agents
  • Expertise across various species, radionuclides and novel administration routes

Preclinical Radiopharmaceutical Therapy Solutions

Bringing new therapeutic radiopharmaceuticals to the market is a complex and challenging process.
Expand

Preclinical Radiopharmaceutical Therapy Solutions

Bringing new therapeutic radiopharmaceuticals to the market is a complex and challenging process. When filing an Investigational New Drug (IND) or Clinical Trial Application (CTA) prior to the initiation of human trials, it is crucial to have strong non-clinical data to support a new candidate. Invicro provides complete preclinical support of your project, including:
  • Study design and consultation
  • Radiolabeling/conjugation to support alpha, beta, and gamma emitting isotopes
  • in vitro/ex vivo cell and tissue-based assays
  • Primary pharmacology studies to demonstrate MOA
  • in vivo Imaging model development to support theranostic imaging
  • Advanced image analytics
  • Dosimetry
  • IND support
  • Development of chemistry, manufacturing and controls package for imaging agents

Learn about Perceptive’s extensive imaging experience and capabilities in:

Oncology

Learn more

Central Nervous System

Learn more

Musculoskeletal

Learn more

Contact us for more information

Contact us

Stay Updated

Never miss a beat. Sign up to receive emails covering industry news and useful content to help you advance clinical development.

"*" indicates required fields

By subscribing, you consent to receive emails from Perceptive. We respect your privacy and you can manage your communication preferences anytime. You can find the Perceptive privacy policy.

This field is for validation purposes and should be left unchanged.

© Perceptive 2024. All Rights Reserved.